Search
for

    GlossaryRU58841 (PSK-3841)

    non-steroidal anti-androgen researched for treating androgenic alopecia

    RU58841 is a non-steroidal anti-androgen that is often researched for its potential to treat androgenic alopecia (pattern hair loss). It works by binding to androgen receptors in the scalp, thereby preventing dihydrotestosterone (DHT) from attaching to these receptors and causing hair follicle miniaturization.

    Related Terms

    Products matching "psk-3841"

    Tracking 1 products like 265 RU-58841 Solution 50mg/ml – 50ml from by companies like Chemyo. View product »

    Learn

    1 / 1 results

      learn RU58841

      a potent but unapproved and potentially problematic topical anti-androgen

    Research

    5 / 13 results

    Community Join

    5 / 8 results

      community I spoke to the Guy who did the Ru58841 (PSK-3841) research

      in Research/Science  291 upvotes 3 years ago
      The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

      community Research about RU58841 /Why it was stopped

      in Research/Science  29 upvotes 3 years ago
      RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

      community For all those worried about a minoxidil break

      in Minoxidil  342 upvotes 4 months ago
      Stopping minoxidil can lead to significant hair loss, but resuming it along with finasteride can help regain lost hair over time. Consistency is key for maintaining hair health and regrowth.
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 4 months ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.